Dermatitis treating agent

Details Dermatitis treating agent Dermatitis treating agent

2011-01-11

2011-01-11

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S339000

Reexamination Certificate

active

07868019

ABSTRACT:
The present invention is to provide a topical dermatitis treating agent which comprises a pyridine compound represented by the following formula [I]:wherein R1and R2each represent a lower alkoxy group, ═X— represents a group represented by the formula:or a group represented by the formula: ═N—, Ring A represents a saturated or unsaturated bicyclic nitrogen-containing heterocyclic group having 1 to 4 substituents selected from hydroxyl group, oxo group, a lower alkoxy group, a di-lower alkylaminophenyl group, a pyperidino-lower alkoxy group, a morpholino-lower alkoxy group, a cyclo-lower alkylamino-lower alkylamino group, pyridyl group and morpholino group, andrepresents a single bond or a double bond,or a pharmaceutically acceptable salt thereof as an active ingredient.

REFERENCES:
patent: 5965730 (1999-10-01), Ukita et al.
patent: 6005106 (1999-12-01), Ukita et al.
patent: 0 748 805 (1996-12-01), None
patent: 0 848 000 (2002-06-01), None
patent: 9-59255 (1997-03-01), None
patent: 10-226685 (1998-08-01), None
patent: 2000-63275 (2000-02-01), None
patent: 2006-151964 (2006-06-01), None
patent: WO 2004/067006 (2004-08-01), None
D. Griswold et al., “SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor α and Interleukin-4 Production in vivo,” The Journal of Pharmacology and Experimental Therapeutics, vol. 287, No. 2, pp. 705-711 (1998).
A. Ehinger et al., “Effects of the Phosphodiesterase 4 Inhibitor RPR 73401 in a Model of Immunological Inflammation,” European Journal of Pharmacology, vol. 392, pp. 93-99 (2000).
W. Baumer et al., “Effects of the Phosphodiesterase 4 Inhibitors SB 207499 and AWD 12-281 on the Inflammatory Reaction in a Model of Allergic Dermatitis,” European Journal of Pharmacology, vol. 446, pp. 195-200 (2002).
I. Iwamoto et al., “Role of CD4+T Lymphocytes and Interleukin-5 in Antigen-Induced Eosinophil Recruitment into the Site of Cutaneous Late-Phase Reaction in Mice,” Journal of Leukocyte Biology, vol. 52, pp. 572-578 (Nov. 1992).
E. Frigas et al., “The Eosinophil and the Pathophysiology of Asthma,” The Journal of Allergy and Clinical Immunology, vol. 77, No. 4, pp. 527-537 (Apr. 1986).
Supplementary European Search Report and Search Opinion for application EP06811270 based on PCT/JP2006/319932, (2006).
Dyke & Montana, “The therapeutic potential of PDE4 inhibitors,” Exp. Opin. Invest. Drugs (1999) 8(9):1301-25.
Kaminuma et al., “A Novel Phosphodiesterase Inhibitor, T-440: Possible Management of Eosinophilic Inflammation by Down-Regulation of Interleukin-5 Production,” Int Arch Allergy Immunol. (1996) 111(suppl 1):16-18.
De Brito et al., “Type 4 Phosphodiesterase Inhibitors and Their Potential in the Treatment of Inflammatory Disease,” Emerging Drugs (1997) 2:249-268.
Ukita et al., “Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridylnaphthalene Derivatives,” J. Med. Chem. (1999) 42:1088-99.
Ukita et al., “Synthesis and Biological Activities of 1-Pyridylisoquinoline and 1-Pyridyldihydroisoquinoline Derivatives as PDE4 Inhibitors,” Bioorganic & Medicinal Chemistry Letters (2003) 13:2347-50.

Affiliated with

Also associated with

Rating

Dermatitis treating agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dermatitis treating agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dermatitis treating agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2630560